Compounded GLP-1 medications can be safe in some situations, but they are not as well validated or consistently regulated as FDA-approved products. For most people who can obtain one, Wegovy, Ozempic, Zepbound, or Mounjaro is the safer and more predictable choice.

Compounding may make sense when an FDA-approved product cannot meet a specific patient need. A licensed clinician should prescribe the medication, and a legitimate state-licensed pharmacy should dispense it. Lower cost or easier access alone is not a medical reason to replace an approved product with a compounded version.

The FDA determined that the injectable semaglutide shortage was resolved on February 21, 2025, and also determined that the tirzepatide injection shortage was resolved. The agency has reported dosing errors involving 5 to 20 times the intended dose with compounded semaglutide.

Compounded GLP-1 Safety at a Glance

Question Short answer
Are compounded semaglutide and tirzepatide FDA-approved? No.
Does the FDA review each compounded product before sale? No.
What are the main extra risks? Incorrect dosing, contamination, inconsistent concentration, fraudulent labeling, and unapproved ingredients.
Are the active ingredients risk-free? No. Compounded products can cause the same serious adverse effects as approved GLP-1 medications.
Which option is preferred when available? An FDA-approved product prescribed and monitored by a clinician.

Why Can Compounded Semaglutide or Tirzepatide Be Riskier?

They can be riskier because the FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

1. Compounded Drugs Do Not Undergo FDA Premarket Review

Poor compounding practices can result in contamination or products containing too much or too little active ingredient. FDA-approved drugs go through FDA review and an approved manufacturing process.

A compounded medication is not the same as a generic version of Wegovy, Ozempic, Zepbound, or Mounjaro. Generic drugs are FDA-approved and must meet specific requirements. Compounded drugs are not approved substitutes.

2. Vials and "Units" Create Dosing Risks

FDA-approved semaglutide products generally use standardized pens or labeled doses. Compounded semaglutide and tirzepatide may come in multidose vials with different concentrations. Instructions may use milligrams, milliliters, or syringe "units," which can make the dose difficult to interpret.

The FDA has reported cases in which patients received much more compounded semaglutide than intended. Reported effects included severe nausea, vomiting, abdominal pain, fainting, dehydration, pancreatitis, and gallstones. Some patients needed medical treatment or hospitalization.

3. Some Products Use Questionable Ingredients or Misleading Labels

The FDA has warned that some compounded semaglutide products contain semaglutide sodium or semaglutide acetate rather than the semaglutide base used in FDA-approved products. The FDA says it does not have enough information to show that these salt forms have the same chemical and pharmacologic properties.

The FDA has also identified fraudulent compounded semaglutide and tirzepatide products with false pharmacy information. Some labels have listed pharmacies that did not make the product or pharmacies that may not exist.

Do not use a product marketed as containing retatrutide or cagrilintide. The FDA says these substances cannot be used in compounding under federal law and have not been established as safe and effective for any condition.

4. Sterility Cannot Be Assumed

Injectable medications must be sterile. Contamination can cause serious infections, including bloodstream infections and sepsis. The FDA has warned patients not to use compounded semaglutide and tirzepatide from a facility with concerns about sterility or manufacturing conditions.

What Side Effects Can Compounded GLP-1 Medications Cause?

Compounded semaglutide and tirzepatide can cause the same medication-related adverse effects as their FDA-approved counterparts.

Common effects include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal pain
  • Reduced appetite
  • Indigestion

More serious risks include pancreatitis, gallbladder disease, kidney injury caused by dehydration, severe gastrointestinal reactions, allergic reactions, and low blood sugar when combined with insulin or certain diabetes medications.

Semaglutide and tirzepatide products also carry warnings about thyroid C-cell tumors based on animal studies. People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications.

Seek Urgent Medical Help For:

  • Severe or persistent abdominal pain, especially pain that spreads to the back
  • Repeated vomiting or inability to keep fluids down
  • Fainting, confusion, or signs of severe dehydration
  • Trouble breathing or swelling of the face, lips, tongue, or throat
  • Symptoms of severe low blood sugar
  • A suspected overdose or major dosing mistake

If you accidentally inject too much compounded semaglutide or tirzepatide, contact your prescriber or pharmacist promptly. In the United States, Poison Control provides free, confidential guidance at 1-800-222-1222.

When Might a Compounded GLP-1 Be Reasonable?

A compounded GLP-1 may be reasonable when an FDA-approved product cannot meet a documented patient need. Before prescribing one, the clinician and patient should confirm that:

  1. The patient has a specific need involving an ingredient, dosage form, or delivery method.
  2. The medication comes from a state-licensed pharmacy or an FDA-registered outsourcing facility.
  3. The prescriber provides an exact dose and titration schedule.
  4. The patient receives instructions in both milligrams and milliliters.
  5. The patient has medical follow-up during treatment.

A previous shortage does not automatically justify using a compounded product. FDA-registered outsourcing facilities operating under section 503B must follow current good manufacturing practice requirements and are subject to FDA inspection. That provides more manufacturing oversight than traditional 503A pharmacy compounding, but a 503B product is still not the same as an FDA-approved medication.

How to Reduce the Risk If You Use a Compounded GLP-1

Before using the medication, verify that:

  • A licensed healthcare professional prescribed it.
  • The pharmacy is state-licensed and provides a verifiable name, address, phone number, lot number, and expiration date.
  • The label clearly states whether the product contains semaglutide or tirzepatide.
  • The concentration is listed in mg/mL.
  • A pharmacist or clinician has explained the syringe markings and prescribed amount.
  • You know whether the dose is weekly and when to take the next dose.
  • The product does not contain semaglutide sodium, semaglutide acetate, retatrutide, or cagrilintide.
  • You are not combining it with another semaglutide, tirzepatide, or GLP-1 medication unless your prescriber specifically instructs you to do so.

Do not inject a product with an unclear label, damaged packaging, unexpected particles, an unexplained color change, or instructions that conflict with what your prescriber told you.

Bottom Line

Treat a compounded GLP-1 as a clinician-supervised exception, not a routine substitute. It should have a documented patient-specific reason, come from a verifiable pharmacy, and include exact dosing instructions and medical follow-up.